il1rn Search Results


recombinant mouse il 1ra  (MedChemExpress)
93
MedChemExpress recombinant mouse il 1ra
Recombinant Mouse Il 1ra, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse il 1ra/product/MedChemExpress
Average 93 stars, based on 1 article reviews
recombinant mouse il 1ra - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
nbp1 32568  (Novus Biologicals)
90
Novus Biologicals nbp1 32568
Nbp1 32568, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nbp1 32568/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
nbp1 32568 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
recombinant murine il 1ra  (Novus Biologicals)
90
Novus Biologicals recombinant murine il 1ra
(A) Osteoclast precursors were generated from primary WT, Myd88 -/- , and Il1r1 -/- BMMs by treatment with 35 ng/mL RANKL treatment for 48 hours. After washing 2X with PBS, fresh media was replenished, and cells were stimulated with vehicle (1% casamino acid-supplemented RPMI) or toxin-deficient S. aureus supernatant (Δ psm ) in the absence of ongoing RANKL treatment. All cells were TRAP stained in vitro at day 6 and TRAP + multinucleated cells were manually quantified using OsteoMeasure software ( n = 3 wells per condition, representative of duplicate experiments). (B) WT and Il1r1 -/- enriched BMMs were stimulated with 35 ng/mL exogenous RANKL for 2 days before stimulating with Δ psm supernatants for four days. In order to determine the contribution of IL-1 signaling in this assay, vehicle (0.1% low endotoxin BSA) or recombinant murine <t>IL-1ra</t> (1 μg/mL) were added during the 2 days of RANKL pre-commitment (BSA, black bars; IL-1ra, grey bars) or during the 4 days of Δ psm supernatant stimulation (indicated by + under each bar). The top line of each bar represents the mean and error bars represent standard deviation. A repeated measures two-way ANOVA with Dunnett’s multiple comparisons test was performed on cell counts from each genotype, comparing each dose of Δ psm supernatant to the vehicle control, where * p < 0.05, *** p < 0.001, **** p < 0.0001, and if not designated by asterisks is non-significant. A repeated measures two-way ANOVA with Tukey’s multiple comparisons test was performed to compare Myd88 -/- and Il1r1 -/- TRAP + multinucleated cell counts to WT counts within each Δ psm supernatant dose, where # p < 0.05, † p < 0.001, and ‡ p < 0.0001. A three-way ANOVA with Tukey’s multiple comparisons test compared the effects of genotype, IL-1ra treatment during RANKL pre-commitment, and IL-1ra treatment during Δ psm supernatant stimulation. Statistical comparisons to WT cells pre-committed with RANKL + BSA and Δ psm supernatant + BSA (first black bar from the left) are reported as @ p < 0.05, or compared to WT cells pre-committed with RANKL + BSA and Δ psm supernatant + IL-1ra (second black bar from the left) are reported as § p < 0.05. Comparisons between all RANKL + IL-1ra pre-commitment conditions (grey bars) were non-significant.
Recombinant Murine Il 1ra, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant murine il 1ra/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
recombinant murine il 1ra - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
rabbit anti il 1ra  (R&D Systems)
90
R&D Systems rabbit anti il 1ra
(A) Osteoclast precursors were generated from primary WT, Myd88 -/- , and Il1r1 -/- BMMs by treatment with 35 ng/mL RANKL treatment for 48 hours. After washing 2X with PBS, fresh media was replenished, and cells were stimulated with vehicle (1% casamino acid-supplemented RPMI) or toxin-deficient S. aureus supernatant (Δ psm ) in the absence of ongoing RANKL treatment. All cells were TRAP stained in vitro at day 6 and TRAP + multinucleated cells were manually quantified using OsteoMeasure software ( n = 3 wells per condition, representative of duplicate experiments). (B) WT and Il1r1 -/- enriched BMMs were stimulated with 35 ng/mL exogenous RANKL for 2 days before stimulating with Δ psm supernatants for four days. In order to determine the contribution of IL-1 signaling in this assay, vehicle (0.1% low endotoxin BSA) or recombinant murine <t>IL-1ra</t> (1 μg/mL) were added during the 2 days of RANKL pre-commitment (BSA, black bars; IL-1ra, grey bars) or during the 4 days of Δ psm supernatant stimulation (indicated by + under each bar). The top line of each bar represents the mean and error bars represent standard deviation. A repeated measures two-way ANOVA with Dunnett’s multiple comparisons test was performed on cell counts from each genotype, comparing each dose of Δ psm supernatant to the vehicle control, where * p < 0.05, *** p < 0.001, **** p < 0.0001, and if not designated by asterisks is non-significant. A repeated measures two-way ANOVA with Tukey’s multiple comparisons test was performed to compare Myd88 -/- and Il1r1 -/- TRAP + multinucleated cell counts to WT counts within each Δ psm supernatant dose, where # p < 0.05, † p < 0.001, and ‡ p < 0.0001. A three-way ANOVA with Tukey’s multiple comparisons test compared the effects of genotype, IL-1ra treatment during RANKL pre-commitment, and IL-1ra treatment during Δ psm supernatant stimulation. Statistical comparisons to WT cells pre-committed with RANKL + BSA and Δ psm supernatant + BSA (first black bar from the left) are reported as @ p < 0.05, or compared to WT cells pre-committed with RANKL + BSA and Δ psm supernatant + IL-1ra (second black bar from the left) are reported as § p < 0.05. Comparisons between all RANKL + IL-1ra pre-commitment conditions (grey bars) were non-significant.
Rabbit Anti Il 1ra, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti il 1ra/product/R&D Systems
Average 90 stars, based on 1 article reviews
rabbit anti il 1ra - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
recombinant il 1ra  (R&D Systems)
90
R&D Systems recombinant il 1ra
(A) Osteoclast precursors were generated from primary WT, Myd88 -/- , and Il1r1 -/- BMMs by treatment with 35 ng/mL RANKL treatment for 48 hours. After washing 2X with PBS, fresh media was replenished, and cells were stimulated with vehicle (1% casamino acid-supplemented RPMI) or toxin-deficient S. aureus supernatant (Δ psm ) in the absence of ongoing RANKL treatment. All cells were TRAP stained in vitro at day 6 and TRAP + multinucleated cells were manually quantified using OsteoMeasure software ( n = 3 wells per condition, representative of duplicate experiments). (B) WT and Il1r1 -/- enriched BMMs were stimulated with 35 ng/mL exogenous RANKL for 2 days before stimulating with Δ psm supernatants for four days. In order to determine the contribution of IL-1 signaling in this assay, vehicle (0.1% low endotoxin BSA) or recombinant murine <t>IL-1ra</t> (1 μg/mL) were added during the 2 days of RANKL pre-commitment (BSA, black bars; IL-1ra, grey bars) or during the 4 days of Δ psm supernatant stimulation (indicated by + under each bar). The top line of each bar represents the mean and error bars represent standard deviation. A repeated measures two-way ANOVA with Dunnett’s multiple comparisons test was performed on cell counts from each genotype, comparing each dose of Δ psm supernatant to the vehicle control, where * p < 0.05, *** p < 0.001, **** p < 0.0001, and if not designated by asterisks is non-significant. A repeated measures two-way ANOVA with Tukey’s multiple comparisons test was performed to compare Myd88 -/- and Il1r1 -/- TRAP + multinucleated cell counts to WT counts within each Δ psm supernatant dose, where # p < 0.05, † p < 0.001, and ‡ p < 0.0001. A three-way ANOVA with Tukey’s multiple comparisons test compared the effects of genotype, IL-1ra treatment during RANKL pre-commitment, and IL-1ra treatment during Δ psm supernatant stimulation. Statistical comparisons to WT cells pre-committed with RANKL + BSA and Δ psm supernatant + BSA (first black bar from the left) are reported as @ p < 0.05, or compared to WT cells pre-committed with RANKL + BSA and Δ psm supernatant + IL-1ra (second black bar from the left) are reported as § p < 0.05. Comparisons between all RANKL + IL-1ra pre-commitment conditions (grey bars) were non-significant.
Recombinant Il 1ra, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant il 1ra/product/R&D Systems
Average 90 stars, based on 1 article reviews
recombinant il 1ra - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
gene exp il1rn mm00446185 m1  (Thermo Fisher)
87
Thermo Fisher gene exp il1rn mm00446185 m1
(A) Osteoclast precursors were generated from primary WT, Myd88 -/- , and Il1r1 -/- BMMs by treatment with 35 ng/mL RANKL treatment for 48 hours. After washing 2X with PBS, fresh media was replenished, and cells were stimulated with vehicle (1% casamino acid-supplemented RPMI) or toxin-deficient S. aureus supernatant (Δ psm ) in the absence of ongoing RANKL treatment. All cells were TRAP stained in vitro at day 6 and TRAP + multinucleated cells were manually quantified using OsteoMeasure software ( n = 3 wells per condition, representative of duplicate experiments). (B) WT and Il1r1 -/- enriched BMMs were stimulated with 35 ng/mL exogenous RANKL for 2 days before stimulating with Δ psm supernatants for four days. In order to determine the contribution of IL-1 signaling in this assay, vehicle (0.1% low endotoxin BSA) or recombinant murine <t>IL-1ra</t> (1 μg/mL) were added during the 2 days of RANKL pre-commitment (BSA, black bars; IL-1ra, grey bars) or during the 4 days of Δ psm supernatant stimulation (indicated by + under each bar). The top line of each bar represents the mean and error bars represent standard deviation. A repeated measures two-way ANOVA with Dunnett’s multiple comparisons test was performed on cell counts from each genotype, comparing each dose of Δ psm supernatant to the vehicle control, where * p < 0.05, *** p < 0.001, **** p < 0.0001, and if not designated by asterisks is non-significant. A repeated measures two-way ANOVA with Tukey’s multiple comparisons test was performed to compare Myd88 -/- and Il1r1 -/- TRAP + multinucleated cell counts to WT counts within each Δ psm supernatant dose, where # p < 0.05, † p < 0.001, and ‡ p < 0.0001. A three-way ANOVA with Tukey’s multiple comparisons test compared the effects of genotype, IL-1ra treatment during RANKL pre-commitment, and IL-1ra treatment during Δ psm supernatant stimulation. Statistical comparisons to WT cells pre-committed with RANKL + BSA and Δ psm supernatant + BSA (first black bar from the left) are reported as @ p < 0.05, or compared to WT cells pre-committed with RANKL + BSA and Δ psm supernatant + IL-1ra (second black bar from the left) are reported as § p < 0.05. Comparisons between all RANKL + IL-1ra pre-commitment conditions (grey bars) were non-significant.
Gene Exp Il1rn Mm00446185 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 87/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp il1rn mm00446185 m1/product/Thermo Fisher
Average 87 stars, based on 1 article reviews
gene exp il1rn mm00446185 m1 - by Bioz Stars, 2026-04
87/100 stars
  Buy from Supplier
gene exp il1rn hs00893626 m1  (Thermo Fisher)
92
Thermo Fisher gene exp il1rn hs00893626 m1
(A) Osteoclast precursors were generated from primary WT, Myd88 -/- , and Il1r1 -/- BMMs by treatment with 35 ng/mL RANKL treatment for 48 hours. After washing 2X with PBS, fresh media was replenished, and cells were stimulated with vehicle (1% casamino acid-supplemented RPMI) or toxin-deficient S. aureus supernatant (Δ psm ) in the absence of ongoing RANKL treatment. All cells were TRAP stained in vitro at day 6 and TRAP + multinucleated cells were manually quantified using OsteoMeasure software ( n = 3 wells per condition, representative of duplicate experiments). (B) WT and Il1r1 -/- enriched BMMs were stimulated with 35 ng/mL exogenous RANKL for 2 days before stimulating with Δ psm supernatants for four days. In order to determine the contribution of IL-1 signaling in this assay, vehicle (0.1% low endotoxin BSA) or recombinant murine <t>IL-1ra</t> (1 μg/mL) were added during the 2 days of RANKL pre-commitment (BSA, black bars; IL-1ra, grey bars) or during the 4 days of Δ psm supernatant stimulation (indicated by + under each bar). The top line of each bar represents the mean and error bars represent standard deviation. A repeated measures two-way ANOVA with Dunnett’s multiple comparisons test was performed on cell counts from each genotype, comparing each dose of Δ psm supernatant to the vehicle control, where * p < 0.05, *** p < 0.001, **** p < 0.0001, and if not designated by asterisks is non-significant. A repeated measures two-way ANOVA with Tukey’s multiple comparisons test was performed to compare Myd88 -/- and Il1r1 -/- TRAP + multinucleated cell counts to WT counts within each Δ psm supernatant dose, where # p < 0.05, † p < 0.001, and ‡ p < 0.0001. A three-way ANOVA with Tukey’s multiple comparisons test compared the effects of genotype, IL-1ra treatment during RANKL pre-commitment, and IL-1ra treatment during Δ psm supernatant stimulation. Statistical comparisons to WT cells pre-committed with RANKL + BSA and Δ psm supernatant + BSA (first black bar from the left) are reported as @ p < 0.05, or compared to WT cells pre-committed with RANKL + BSA and Δ psm supernatant + IL-1ra (second black bar from the left) are reported as § p < 0.05. Comparisons between all RANKL + IL-1ra pre-commitment conditions (grey bars) were non-significant.
Gene Exp Il1rn Hs00893626 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp il1rn hs00893626 m1/product/Thermo Fisher
Average 92 stars, based on 1 article reviews
gene exp il1rn hs00893626 m1 - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
gene exp il1rn rn02586400 m1  (Thermo Fisher)
89
Thermo Fisher gene exp il1rn rn02586400 m1
(A) Osteoclast precursors were generated from primary WT, Myd88 -/- , and Il1r1 -/- BMMs by treatment with 35 ng/mL RANKL treatment for 48 hours. After washing 2X with PBS, fresh media was replenished, and cells were stimulated with vehicle (1% casamino acid-supplemented RPMI) or toxin-deficient S. aureus supernatant (Δ psm ) in the absence of ongoing RANKL treatment. All cells were TRAP stained in vitro at day 6 and TRAP + multinucleated cells were manually quantified using OsteoMeasure software ( n = 3 wells per condition, representative of duplicate experiments). (B) WT and Il1r1 -/- enriched BMMs were stimulated with 35 ng/mL exogenous RANKL for 2 days before stimulating with Δ psm supernatants for four days. In order to determine the contribution of IL-1 signaling in this assay, vehicle (0.1% low endotoxin BSA) or recombinant murine <t>IL-1ra</t> (1 μg/mL) were added during the 2 days of RANKL pre-commitment (BSA, black bars; IL-1ra, grey bars) or during the 4 days of Δ psm supernatant stimulation (indicated by + under each bar). The top line of each bar represents the mean and error bars represent standard deviation. A repeated measures two-way ANOVA with Dunnett’s multiple comparisons test was performed on cell counts from each genotype, comparing each dose of Δ psm supernatant to the vehicle control, where * p < 0.05, *** p < 0.001, **** p < 0.0001, and if not designated by asterisks is non-significant. A repeated measures two-way ANOVA with Tukey’s multiple comparisons test was performed to compare Myd88 -/- and Il1r1 -/- TRAP + multinucleated cell counts to WT counts within each Δ psm supernatant dose, where # p < 0.05, † p < 0.001, and ‡ p < 0.0001. A three-way ANOVA with Tukey’s multiple comparisons test compared the effects of genotype, IL-1ra treatment during RANKL pre-commitment, and IL-1ra treatment during Δ psm supernatant stimulation. Statistical comparisons to WT cells pre-committed with RANKL + BSA and Δ psm supernatant + BSA (first black bar from the left) are reported as @ p < 0.05, or compared to WT cells pre-committed with RANKL + BSA and Δ psm supernatant + IL-1ra (second black bar from the left) are reported as § p < 0.05. Comparisons between all RANKL + IL-1ra pre-commitment conditions (grey bars) were non-significant.
Gene Exp Il1rn Rn02586400 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 89/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp il1rn rn02586400 m1/product/Thermo Fisher
Average 89 stars, based on 1 article reviews
gene exp il1rn rn02586400 m1 - by Bioz Stars, 2026-04
89/100 stars
  Buy from Supplier
gene exp il1rn hs00277299 m1  (Thermo Fisher)
88
Thermo Fisher gene exp il1rn hs00277299 m1
Primers and probes for the quantification of gene expression using Taq man low-density arrays (TLDAs).
Gene Exp Il1rn Hs00277299 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp il1rn hs00277299 m1/product/Thermo Fisher
Average 88 stars, based on 1 article reviews
gene exp il1rn hs00277299 m1 - by Bioz Stars, 2026-04
88/100 stars
  Buy from Supplier
gene exp il1rn mm00446186 m1  (Thermo Fisher)
97
Thermo Fisher gene exp il1rn mm00446186 m1
Primers and probes for the quantification of gene expression using Taq man low-density arrays (TLDAs).
Gene Exp Il1rn Mm00446186 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp il1rn mm00446186 m1/product/Thermo Fisher
Average 97 stars, based on 1 article reviews
gene exp il1rn mm00446186 m1 - by Bioz Stars, 2026-04
97/100 stars
  Buy from Supplier

Image Search Results


(A) Osteoclast precursors were generated from primary WT, Myd88 -/- , and Il1r1 -/- BMMs by treatment with 35 ng/mL RANKL treatment for 48 hours. After washing 2X with PBS, fresh media was replenished, and cells were stimulated with vehicle (1% casamino acid-supplemented RPMI) or toxin-deficient S. aureus supernatant (Δ psm ) in the absence of ongoing RANKL treatment. All cells were TRAP stained in vitro at day 6 and TRAP + multinucleated cells were manually quantified using OsteoMeasure software ( n = 3 wells per condition, representative of duplicate experiments). (B) WT and Il1r1 -/- enriched BMMs were stimulated with 35 ng/mL exogenous RANKL for 2 days before stimulating with Δ psm supernatants for four days. In order to determine the contribution of IL-1 signaling in this assay, vehicle (0.1% low endotoxin BSA) or recombinant murine IL-1ra (1 μg/mL) were added during the 2 days of RANKL pre-commitment (BSA, black bars; IL-1ra, grey bars) or during the 4 days of Δ psm supernatant stimulation (indicated by + under each bar). The top line of each bar represents the mean and error bars represent standard deviation. A repeated measures two-way ANOVA with Dunnett’s multiple comparisons test was performed on cell counts from each genotype, comparing each dose of Δ psm supernatant to the vehicle control, where * p < 0.05, *** p < 0.001, **** p < 0.0001, and if not designated by asterisks is non-significant. A repeated measures two-way ANOVA with Tukey’s multiple comparisons test was performed to compare Myd88 -/- and Il1r1 -/- TRAP + multinucleated cell counts to WT counts within each Δ psm supernatant dose, where # p < 0.05, † p < 0.001, and ‡ p < 0.0001. A three-way ANOVA with Tukey’s multiple comparisons test compared the effects of genotype, IL-1ra treatment during RANKL pre-commitment, and IL-1ra treatment during Δ psm supernatant stimulation. Statistical comparisons to WT cells pre-committed with RANKL + BSA and Δ psm supernatant + BSA (first black bar from the left) are reported as @ p < 0.05, or compared to WT cells pre-committed with RANKL + BSA and Δ psm supernatant + IL-1ra (second black bar from the left) are reported as § p < 0.05. Comparisons between all RANKL + IL-1ra pre-commitment conditions (grey bars) were non-significant.

Journal: PLoS Pathogens

Article Title: MyD88 and IL-1R signaling drive antibacterial immunity and osteoclast-driven bone loss during Staphylococcus aureus osteomyelitis

doi: 10.1371/journal.ppat.1007744

Figure Lengend Snippet: (A) Osteoclast precursors were generated from primary WT, Myd88 -/- , and Il1r1 -/- BMMs by treatment with 35 ng/mL RANKL treatment for 48 hours. After washing 2X with PBS, fresh media was replenished, and cells were stimulated with vehicle (1% casamino acid-supplemented RPMI) or toxin-deficient S. aureus supernatant (Δ psm ) in the absence of ongoing RANKL treatment. All cells were TRAP stained in vitro at day 6 and TRAP + multinucleated cells were manually quantified using OsteoMeasure software ( n = 3 wells per condition, representative of duplicate experiments). (B) WT and Il1r1 -/- enriched BMMs were stimulated with 35 ng/mL exogenous RANKL for 2 days before stimulating with Δ psm supernatants for four days. In order to determine the contribution of IL-1 signaling in this assay, vehicle (0.1% low endotoxin BSA) or recombinant murine IL-1ra (1 μg/mL) were added during the 2 days of RANKL pre-commitment (BSA, black bars; IL-1ra, grey bars) or during the 4 days of Δ psm supernatant stimulation (indicated by + under each bar). The top line of each bar represents the mean and error bars represent standard deviation. A repeated measures two-way ANOVA with Dunnett’s multiple comparisons test was performed on cell counts from each genotype, comparing each dose of Δ psm supernatant to the vehicle control, where * p < 0.05, *** p < 0.001, **** p < 0.0001, and if not designated by asterisks is non-significant. A repeated measures two-way ANOVA with Tukey’s multiple comparisons test was performed to compare Myd88 -/- and Il1r1 -/- TRAP + multinucleated cell counts to WT counts within each Δ psm supernatant dose, where # p < 0.05, † p < 0.001, and ‡ p < 0.0001. A three-way ANOVA with Tukey’s multiple comparisons test compared the effects of genotype, IL-1ra treatment during RANKL pre-commitment, and IL-1ra treatment during Δ psm supernatant stimulation. Statistical comparisons to WT cells pre-committed with RANKL + BSA and Δ psm supernatant + BSA (first black bar from the left) are reported as @ p < 0.05, or compared to WT cells pre-committed with RANKL + BSA and Δ psm supernatant + IL-1ra (second black bar from the left) are reported as § p < 0.05. Comparisons between all RANKL + IL-1ra pre-commitment conditions (grey bars) were non-significant.

Article Snippet: To test the specific role of IL-1R inhibition on S . aureus -enhanced osteoclast differentiation, osteoclastogenesis assays in WT and Il1r1 -/- cells were conducted with the addition of a vehicle control (0.1% low endotoxin BSA) or 1 μg/mL recombinant murine IL-1ra (Novus Biologicals, LLC, Littleton, CO, NBP2-35105) during the 2 days of RANKL pre-commitment or during the 4 days of Δ psm supernatant stimulation.

Techniques: Generated, Staining, In Vitro, Software, Recombinant, Standard Deviation, Control

Primers and probes for the quantification of gene expression using Taq man low-density arrays (TLDAs).

Journal:

Article Title: Differential expression of immunoregulatory genes in monocytes in response to Porphyromonas gingivalis and Escherichia coli lipopolysaccharide

doi: 10.1111/j.1365-2249.2009.03920.x

Figure Lengend Snippet: Primers and probes for the quantification of gene expression using Taq man low-density arrays (TLDAs).

Article Snippet: RNA polymerase II (Hs00172187_ml) was used as an endogenous control. table ft1 table-wrap mode="anchored" t5 caption a7 Inflammatory mediator Primers and probe assay ID IL-1α (interleukin-1 alpha) Hs00174092_m1 IL-1β (interleukin-1 beta) Hs00174097_m1 IL-Ra (interleukin-1 receptor antagonist) Hs00277299_m1 IL-1R1 (interleukin-1 receptor-1) Hs00168392_m1 IL-1Acp (interleukin-1 accessory protein) Hs00370506_m1 ICE (IL-1 converting enzyme) (caspase-1) Hs00354836_m1 IL-18 (interleukin-18) Hs00155517_m1 IL-18R1 (interleukin-18 receptor) Hs00175381_m1 IL-18Acp (interleukin-1 accessory protein) Hs00187256_m1 IL-1F6 (interleukin-1 family 6) Hs00205367_m1 IL-1F7 (interleukin-1 family 7) Hs00367199_m1 IL-1F8 (interleukin-1 family 8) Hs00758166_m1 IL-1F9 (interleukin-1 family 9) Hs00219742_m1 IL-1F10 (interleukin-1 family 10) Hs00544661_m1 IL-1Rrp2 (IL-1 receptor-related protein 2) Hs00187259_m1 TNF-α (tumour necrosis factor alpha) Hs00174128_m1 TNFRSF1A (TNF alpha receptor superfamily 1A) Hs00236902_m1 TNFRSF1B (TNF alpha receptor superfamily 1B) Hs00153550_m1 TACE (TNF-α converting enzyme) Hs00234221_m1 IL-4 (interleukin-4) Hs00174122_m1 IL-6 (interleukin-6) Hs00174131_m1 OSM (oncostatin M) Hs00171165_m1 LIF (leukaemia inhibitory factor) Hs00171455_m1 OSMR (oncostatin M receptor) Hs00384278_m1 LIFR (leukaemia inhibitory factor receptor) Hs00158730_m1 IL-10 (interleukin 10) Hs00174086_m1 IL-12a (interleukin-12 chain a) Hs00168405_m1 IL-12b (interleukin-12 chain b) Hs00233688_m1 IL-32 (interleukin-32) Hs00170403_m1 GM-CSF (granulocyte macrophage-colony stimulating factor) Hs00171266_m1 IFN-γ (interferon gamma) Hs00174143_m1 CCL2 (monocyte chemottractant protein 1) Hs00234140_m1 CX3CL1 (fractalkine) Hs00171086_m1 CXCL5 (epithelial-derived neutrophil activating protein 78) (ENA-78) Hs00607029_g1 CCL5 (regulation on activation normal T cell expressed and secreted) (RANTES) Hs00174575_m1 CXCL8 (IL-8) Hs00174103_m1 CXCL10 Hs00171042_m1 Leptin Hs00174877_m1 LeptinR (leptin receptor) Hs00174497_m1 ADIPOR1 (adiponectin receptor-1) Hs00360422_m1 ADIPOR2 (adiponectin receptor-2) Hs00226105_m1 Visfatin Hs00237184_m1 INSR (insulin receptor) Hs00169631_m1 RAGE (receptor for advanced glycation end products) Hs00153957_m1 CD14 Hs00169122_g1 Control genes GAPDH (glyceraldehyde-3-phosphate-dehydrogenase) Hs99999905_m1 18S Hs99999901_s1 RNA pol II Hs00222679_m1 Open in a separate window Primers and probes for the quantification of gene expression using Taq man low-density arrays (TLDAs).

Techniques: Gene Expression, Activation Assay, Control